CURRICULUM VITAE

SHAWN WALKER ROBINSON, M.D.

Assistant Professor of Medicine

Assistant Professor of Physiology (Secondary)

University of Maryland School of Medicine

## July 1, 2017

**Contact information**

Business Address: Department of Medicine

110 South Paca, 7th Floor

Baltimore, Maryland 21201

Business Phone Number: 410-328-8788

Fax: 410-328-1048

E-mail: srobinso@som.umaryland.edu

**Education**

1983 AB, Biochemistry Brown University

1988 M.D. University of Maryland School of Medicine (UMSOM)

**Post Graduate Education and Training**

1988-1989 Internship, Internal Medicine, University of Maryland Medical Center (UMMC)

1989-1991 Residency, Internal Medicine, UMMC

1991-1995 Fellowship, Cardiology, The Johns Hopkins School of Medicine

**Certification**

1989 Diplomat: National Board of Medical Examiners

1991 Diplomat: American Board of Internal Medicine, (ABIM)

1995 Diplomat: ABIM, Cardiovascular Disease

2005 Re-certified, ABIM, Cardiovascular Disease

2010 Diplomat: ABIM, Advanced Heart Failure/Transplant Cardiology

2016 Re-certified, ABIM, Cardiovascular Disease

**Medical Licensure**

Active Maryland

**Employment History**

Academic Appointments

1990-1991 Assistant Instructor in Medicine, Department of Medicine, UMSOM

1995-1996 Instructor in Medicine, Division of Cardiology, The Johns Hopkins Hospital

1996-present Assistant Professor of Medicine, Cardiology, UMSOM

1996-present Assistant Professor of Physiology (Secondary), UMSOM

2001-2012 Faculty Associate, University of Maryland School of Nursing

**Professional Memberships**

1994-present American Heart Association, General Member,

1996-2000, 2012 Heart Failure Society of America, General

**Awards and Fellowships**

1985 American Heart Association Medical Student Research Fellowship

1988 Excellence in Research Award, U. of MD. School of Medicine

1991 NIH training grant recipient (5T32HL07227-17)

1994-1998 Robert Wood Johnson- Harold Amos Medical Faculty Development Fellowship. [Mentor: Douglas M. Fambrough, The Johns Hopkins University, Departments of Biology and Biophysics].

1. Provost Award for Undergraduate Research, The Johns Hopkins University. (Served as Mentor to JHU undergraduate)

1999 Henry C. Welcome Fellowship Grant, Maryland Higher Education Commission.

2008 Theodore E. Woodward Faculty Prize in Medicine (awarded by Medical Housestaff to one Medicine Faculty member annually)

2015 Theodore E. Woodward Faculty Prize in Medicine

### Clinical Activities

**Clinical Expertise**

Board certified Cardiologist

Additional board certification in the sub-specialty of Advanced heart failure and transplant.

Clinical and Research focus in the areas of Acute and Chronic heart failure management, and the potential influence of pharmacogenomics on disease management.

**Scope of Clinical Practice**

1996-present Congestive Heart failure (shared) clinic, VAMC. ~ 420 pts/year

1996-2011 General Cardiology (individual) clinic, UMSOM Faculty practice ~250 pts/year

2004-present Cardiomyopathy (shared) clinic, UMSOM Faculty practice ~1000 pts/yr

1996-present Service attending, CCU (UMMC & VA), Cardiology consults. 3-4 months/year

1996-present ECG, holter, stress test interpretation ~5000/yr (VAMC-only starting in 2009)

2008-2016 Echo interpretation ~ 500-900/year at UMMC

2017-present Echo interpretation ~2000/yr at VAMC

### Administrative Service

#### Institutional Service

1997-present Applicant interviewer for Medical School admissions, UMSOM

1999-present Applicant interviewer for Medical Residency Program, UMMC

1999-present Applicant interviewer for Cardiology Fellowship program, UMMC

## 1999-2001 School of Medicine Research Advisory Committee, UMSOM

1999 School of Medicine Faculty Mentoring Advisory Committee, UMSOM

1999 Judge, Medical Student Research Day, UMSOM

1999 Speaker, White Coat Ceremony, UMSOM

2000 Intramural grant review committee, clinical trials study section, UMSOM

1998-2000 Representative, School of Medicine Council, UMSOM

2001-present Intramural grant ad hoc review, UMSOM

2000-2002 Medical Student Education Task Force, Dept. of Medicine, UMSOM

2002 Academic Appeals Committee, case review of MSI, UMSOM

2003-2004 Faculty Assembly Representative for Department of Medicine, UMSOM

2003 Academic Appeals Committee, case review of MSII, MD/PhD candidate, UMSOM

2005 UMSOM Mini-med school – Cumberland Maryland

2005 Academic Appeals Committee, case review of MSIV, UMSOM

2005-2011 Medical Director, Cardiac Intensive & Progressive Care Units, UMMC

2007, 2011 Mini-Med school for Kids – Boys & Girls Club of Baltimore, topic Heart Health, UMSOM

2007-present Core Teaching Faculty, Internal Medicine Residency program, UMMC

2009-present Clinical Competency Committee, Department of Medicine Residency program, UMMC

2011 White Coat Ceremony, “Coater”, UMSOM

2011-present Cardiology Section Chief, VA Maryland Health Care Systems (VAMHCS)

# **Local Service**

2002-2006 Clinical Events Committee: Vascular Interaction with Age in Myocardial

Infarction. PI: Steve Schulman, MD. JHMI, 5R01HL070059-02

2012-2013 Clinical Events Adjudication Committee (CEAC) for the PAPI-2 Study

PI: Alan Shuldiner, MD 9 U01 HL105198

2014-present Rescuing Circulating Angiogenic Cell Function (HP-00057124) Sub-Investigator

2015-present VAMC GRECC research subject screening stress test adjudication

#### National Service

2004 - 2007 AHA Grant review committee, Mid-Atlantic region

2001-present reviewer: *Journal of National Medical Association* (1 per year)

2006-present reviewer: *Journal of American College of Cardiology (0-1 per year)*

2016-present reviewer: *Journal of Cardiac Failure 1 per year*

2007-2010 reviewer: *International Journal of Cardiology (0-1 per year)*

2010-2013 reviewer: *The Journal of Clinical Pharmacology 1 per year*

**Teaching Service**

Undergraduate Student Teaching

1997, 2001, Advanced Premedical Summer Enrichment Program, research mentor to 1 or 2

2003, 2004 undergraduate students, daily contact during the summer.

Medical Student Teaching (1st and 2nd yr medical students)

Non-seq. yrs Preceptor, Physical diagnosis (ICM-2) ‘97-‘98, ‘01-‘02, ‘05-‘06, ‘12-’13

(Groups of 2, 4 or 6 2nd yr med students)

1998-2016 Cardiac Physical diagnosis for 2nd year medical students

(two 2-hour sessions/yr, 6-8 students per session)

2000-2004, Small group discussion leader Cardiac physiology MS I,

(8-12 hours per year, 16-20 students per session)

2000-present MSPR 522 Pathophysiology and Therapeutics small group discussion leader

(10-12 2 hour sessions per year, 16-20 students per session)

2003-present MPHY 501, Functional systems, Integrative function, Clinical correlation, CHF (1 hour lecture followed by patient interview) (entire class of ~160 1st yr students)

## 2005-2006 MPHY 501 – Cardiovascular physiology, Clinical correlation, Hemodynamics of

## Shock (1 hour lecture) (entire class of ~160 1st yr students)

## 2009-present Course director, Cardiac section, MSPR 521 Pathophysiology and Therapeutics I

2012-present Lecturer MSPR 522 (three 1 hr lectures/ yr) (entire class of ~160 2nd yr students)

Resident and Fellow Teaching (PGY 1-7)

1996-present Cardiology service attending 3 months/yr

1997-present Annual Acute Care Medicine Lecture series for medical residents, “Hypertensive Emergencies”, “Acute Congestive Heart Failure”, or “Acute Coronary Syndrome”

1998-present Mentor to medical residents in Department of Medicine, 1 per PGY level.

1998-2004 Ambulatory Care Lecture for medical residents, “Diastolic Dysfunction HF

2007-present UM Faculty practice CHF clinic 4.5 hrs contact with 2-3 fellows weekly

2008-present VA hospital Cardiology Fellows clinic preceptor, (18 clinic sessions/yr)

Thesis committee participation

2004-2005 Thesis committee, Gentzon Hall, MD, PhD graduate (Biochemistry)

2006-2007 Thesis committee, Jaclyn Kerr, PhD candidate (Physiology)

2008-2009 Thesis committee, Hobart Rogers, PharmD

2011-2012 Thesis committee, Barbara Brady, PhD candidate Nursing School

**Grant Support:**

**Active**

1/2016- NHLBI Multi-center Registry NCT01369407 REVIVAL: Registry Evaluation of

Vital Information for VADs in Ambulatory Life) (HP-00067274) Duration: 2yrs

Role: UM, Baltimore site PI ($25,160).

9/2017 - GALCTIC-HF study sponsored by Amgen Inc. A Double-blind, Randomized,

Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of

Omecamtiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart

Failure with Reduced Ejection Fraction. Expected duration: 4 yrs

Role: VAMC, Baltimore site PI

**Completed Research (PI)**

7/97 – 6/99: American Heart Association, Maryland Affiliate, Beginning Grant-In-Aid: “Adenoviral-mediated expression of sodium/potassium ATPase subunits in cardiac myocytes” (Total $66,000, indirect $6,000)

7/98 – 6/99: University of Maryland Intramural Grant ($20,000)

7/99 – 6/04: NIH, NHLBI K01HL04051-01: “Effects of Na,K-ATPase Alpha Isoforms on Contractility” (Total direct $526,248.00)

7/04 – 6/05: Intramural Grant: Genomic Screening in Patients at Risk for Sudden Cardiac Death. Role on project: PI, ($15,000)

2005-2006: GCRC funding support for genomic services in Core lab. Role: PI ($5000)

2005-2007 Paracor Ventricular Support System, Industry Sponsored trial role: site PI

2006-2007 Other Tobacco Related Diseases Grant: Identifying Phosphodiesterase type IV D

genetic associations with cardiovascular disease. Role: PI ($50,000)

**Publications**

Peer-reviewed journal articles

1. Marban E, **Robinson SW**, Wier WG. 1986. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle.  *J. Clin. Invest.* **78**: 1185-1192.
2. Martin LW, Johnson RA, Scott H, **Robinson SW**, Beauman G, Englehardt G, Vogel R. Impedance measurement of absolute blood flow using a standard angioplasty catheter. *Am. Heart J.* **121**: 745- 752, 1991.
3. Gottlieb SS, **Robinson SW**, Krichten CM, Fisher ML. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am. J. of Cardiology* **70**(9): 890-3, 1992.
4. Gottlieb SS, **Robinson SW**, Weir R, Fisher ML, Krichten CM. Determinants of renal response to ACE inhibition in patients with congestive heart failure. *Am. Heart J.* **124**(1): 131-6, 1992.
5. **Robinson SW**, Cho PW, Levitsky HI, Olson JL, Hruban RH, Acker MA, Kessler PD. Arterial delivery of genetically labeled skeletal myoblasts to the heart: Long-term survival and phenotypic modification of implanted myoblasts. *Cell Transplantation* **5(1)**: 77-91, 1996.
6. Kaprielian Z, **Robinson SW\***, Fambrough DM, Kessler PD. Movement of Ca2+-ATPase molecules within the sarcoplasmic/endoplasmic reticulum in skeletal muscle. *J Cell Sci* **109**: 2529-2537, 1996. **\***(The first two authors contributed equally)
7. Schultheis LW, Balser JR, Calkins H, **Robinson SW**, Weiss JL, Sussman M, Stuart RS. High dose neostigmine treatment of malignant sinus tachycardia*. Pacing Clin. Electrophysiol*. **20**(5 Pt 1): 1369-1372, 1997.
8. Gottlieb SS, Fisher ML, Freudenberger R, **Robinson S**, Zietowski G, Alves L, Krichten C, Vaitkevicus P, McCarter R. Effects of exercise training on peak performance and quality of life in congestive heart failure patients. J Card Fail. 1999 Sep;5(3):188-94.
9. Wilson PD, Devuyst O, Li X, Gatti L, Falkenstein D, **Robinson S**, Fambrough D,

Burrow CR. Apical Plasma Membrane Mispolarization of NaK-ATPase in Polycystic Kidney Disease Epithelia Is Associated with Aberrant Expression of the beta2 Isoform. Am J Pathol., Jan;**156**(1):253-268, 2000.

1. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, **Robinson SW**, Gottlieb SS. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. Apr 18;132(8):636-40, 2000.Freudenberger R, Sikora JA, Gottlieb S, **Robinson S**, Fisher M. Characteristics of patients referred for cardiac transplantation: implications for the donor organ shortage. Am Heart J. Dec;140(6):857-61, 2000.
2. Freudenberger R, Sikora JA, Gottlieb S, **Robinson S**, Fisher M. Characteristics of patients referred for cardiac transplantation: implications for the donor organ shortage. Am Heart J. Dec;140(6):857-61, 2000.
3. Skotzko CE, Krichten C, Zietowski G, Alves L, Freudenberger R, **Robinson S**, Fisher M, Gottlieb SS. Depression is common and precludes accurate assessment of functional status in elderly patients with congestive heart failure. J Card Fail. Dec;6(4):300-5, 2000.
4. Chen-Izu Ye, Shorofsky SR, **Robinson SW**, Wier WG, Goldman L, Balke W ICa(TTX) Channels are distinct from those generating the classical cardiac Na+ current. Biophys J. 2001 Nov;81(5):2647-59.
5. Blaustein MP, Golovina VA, Song H, Choate J, Lencesova L, **Robinson SW**, Wier WG., Organization of Ca2+ stores in vascular smooth muscle: functional implications.Novartis Found Symp 2002;246:125-37; discussion 137-41, 221-7
6. [Sha Q, **Robinson SW**, McCulle SL, Shorofsky SR, Welling PA, Goldman L, Balke CW.](http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12562928&dopt=Abstract)  An antisense oligonucleotide against H1 inhibits the classical sodium current but not ICa(TTX) in rat ventricular cells. J Physiol. 2003 Mar 1;547(Pt 2):435-40.
7. Zhou X, Yin W, Doi SQ, **Robinson SW**, Takeyasu K, Fan X. Stimulation of Na,K-ATPase by low potassium requires reactive oxygen species.Am J Physiol Cell Physiol. 2003 Aug; 285(2): C319-26.
8. Blaustein MP, **Robinson SW**, Gottlieb SS, Balke CW, Hamlyn JM.Sex, digitalis, and the sodium pump. Mol Interv. 2003 Mar;3(2):68-72.
9. Gottlieb SS, Khatta M, Friedmann E, Einbinder L, Katzen S, Baker B, Marshall J, Minshall S, **Robinson S**, Fisher ML, Potenza M, Sigler B, Baldwin C, Thomas SA. The influence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol. 2004 May 5;43(9):1542-9.
10. [Rao K](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Rao%20K%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Fisher ML](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fisher%20ML%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [**Robinson S**](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Robinson%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Shorofsky S](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Shorofsky%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus), [Gottlieb SS](http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Gottlieb%20SS%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus). Effect of chronic changes in heart rate on congestive heart failure. J Card Fail. 2007 May;13(4):269-74.
11. Rogers HL, Marshall J, Bock J, Dowling TC, Feller E, **Robinson S**, Gottlieb SS. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. 2008 Feb;14(1):1-5.
12. Parsa A, Chang YP, Kelly RJ, Corretti MC, Ryan KA, **Robinson SW**, Gottlieb SS, Kardia SL, Shuldiner AR, Liggett SB. Hypertrophy-associated polymorphisms ascertained in a founder cohort applied to heart failure risk and mortality.Clin Transl Sci. 2011 Feb;4(1):17-23
13. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, **Robinson SW,** et.al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther. 2013 Aug;94(2):207-10. doi: 10.1038/clpt.2013.59. Epub 2013 Mar 19. PMID: 23588301
14. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, Bhatty S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshees AL, **Robinson SW**, Blitzer MG, McArdle PF, Brown L, Jeng LJB, Zhao RY, Ambulos N, Vesely MR. 2014. Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program. Am J Med Genet Part C 166C:76–84
15. Vesely MR, Benitez RM, **Robinson SW**, Collins JA, Dawood MY, Gammie JS. Surgical and Transcatheter Mitral Valve Repair for Severe Chronic Mitral Regurgitation: A Review of Clinical Indications and Patient Assessment. J Am Heart Assoc. 2015 Dec 11;4(12).
16. Landers-Ramos RQ, Sapp RM, VandeWater E, Macko J, **Robinson S**, Wang Y, Chin ER, Spangenburg EE, Prior SJ, Hagberg JM. Investigating the extremes of the continuum of paracrine functions in CD34-/CD31+ CACs across diverse populations. Am J Physiol Heart Circ Physiol. 2017 Jan 1;312(1):H162-H172.
17. Harris KM, Krantz DS, Kop WJ, Marshall J, **Robinson SW**, Marshall JM, Gottlieb SS. A New Clinically Applicable Measure of Functional Status in Patients With Heart Failure: The 60-Foot Walk Test JACC Heart Fail. 2017 Jun;5(6):411-420.
18. Larisa H. Cavallari, PharmD,1 Craig R. Lee, PharmD, PhD2, Amber L. Beitelshees, PharmD, MPH,3 Julio D. Duarte, PharmD, PhD,4 Deepak Voora, MD,5 Stephen E. Kimmel, MD,6 Rhonda M. Cooper-DeHoff, PharmD, MS,1,7 Caitrin W. McDonough, PhD,1 Yan Gong, PhD,1 Chintan V. Dave, PharmD,8 Victoria M. Pratt, PhD,9 Tameka D. Alestock,3 R. David Anderson, MD,7 Jorge Alsip, MD,10 Amer K. Ardati, MD,4 Brigitta C. Brott, MD,10 Lawrence Brown,MD,11 Supatat Chumnumwat, PharmD,4 Michael J. Clare-Salzler, MD,12 James C. Coons, PharmD,13 Joshua C. Denny, MD, MS,14 Chrisly Dillon,15 Amanda R. Elsey, MHA,1 Issam Hamadeh, PharmD,1 Shuko Harada, MD,16 William B. Hillegass, MD,17 Lindsay Hines, PhD,18 Richard DB. Horenstein, MD, JD,3 Lucius A. Howell, MD,19 Linda J.B. Jeng, MD,PhD3 Mark D. Keleman, MD,3 Y.M. Lee, PharmD,4 Oyunbileg Magvanjav,1 May Montasser, PhD,3 David R. Nelson, MD,20 Edith A. Nutescu, PharmD, MS,4 Devon C. Nwaba, MPH,3 Ruth E. Pakyz,3 Kathleen Palmer,3 Josh F. Peterson, MD, MPH,14 Toni I. Pollin, MDMS, PhD,3 Alison H. Quinn, PharmD,4 **Shawn W. Robinson, MD**,3,11 Jamie Schub,3 Todd C. Skaar, PhD,21 Donald M. Smith, PharmD,1 Vindhya B. Sriramoju, MD,19 Petr Starostik, MD,12 Tomasz P. Stys, MD,22 James M. Stevenson, PharmD, MS,13 Nicholas Varunok, MS,19 Mark R. Vesely, MD,2 3,11 Dyson Wake, PharmD,1 Karen E. Weck, MD,23 Kristin W. Weitzel, PharmD,1 Russell A. Wilke, MD,22 James Willig, MD,10 Richard Y. Zhao, MS, PhD,24 Rolf P. Kreutz, MD,21 George A. Stouffer, MD,19 Philip E. Empey, PharmD, PhD,13 Nita A. Limdi, PharmD, PhD,25 Alan R. Shuldiner, MD,3 Almut G. Winterstein, PhD,8,26 Julie A. Johnson, PharmD,1,10 on behalf of the IGNITE Network Pharmacogenetics Working GroupProspective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy after PCI: a Multi-Site Investigation of Cardiovascular Outcomes in a Real-World Setting. *Accepted* JACC-Clinical Interventions.

Articles (Non-Refereed)

1. Freudenberger RS, Gottlieb SS, **Robinson SW**, Fisher ML. A four-part regimen for clinical heart failure. Hosp Pract (Off Ed) 1999 Sep 1;34(9):51-6, 59-64.
2. **Robinson, Shawn W**., Saunders, Elijah. Will race matter in the era of personalized medicine? Cardiology Today, September 2009.

Book Chapters

1. Fain, J.N., Lin, S.-H., Randazzo, P., **Robinson, S**. and Wallace, M. Hormonal regulation of glycogen phosphorylase in rat hepatocytes: Activation of phosphatidylinositol breakdown by vasopressin and alpha1 catecholamines. In: Isolation, Characterization and Use of Hepatocytes, R. A. Harris and N.W. Cornell, eds., Elsevier Pub. Co., 441-418, 1983.
2. Marban E, **Robinson SW**, Wier WG, Kitakaze M, Martin M, Yue DT, Chacko VP. 1989. Calcium metabolism in enzymatically dissociated rat heart cells and in intact perfused ferret hearts. In Analysis and Simulation of the Cardiac System - Ischemia. S. Sideman and R. Beyar, editors. CRC Press, N.Y., pp421-436.
3. **Robinson SW**, Acker MA, Byrne BJ and Kessler PD. 1997. Implantation of Skeletal Myoblast-Derived Cells. In Cellular Cardiomyoplasty:Myocardial Repair with Cell Implantation. R.L.Kao and R.C.J.Chiu, editors. R.G.Landes Co., pp79-104.

**Abstracts**

1. Wier WG, **Robinson SW**, Marban E. 1986. [Ca2+]i-transients measured with Fura-2 in single isolated rat ventricular cells. *J Gen Physio* **88**: p60a.
2. **Robinson SW**, Marban E, and Wier WG. 1986. Do rat heart cells exhibit spontaneous Ca2+ oscillations under physiological conditions? *Circ* **74**: p II-172.
3. Marban E, **Robinson SW**, and Wier WG. 1986. Mechanisms of arrhythmogenic delayed and early afterdepolarizations in ferret ventricular muscle: Role of activation by intracellular calcium. *Circ* **74**: p II-419.
4. Gottlieb SS, **Robinson SW**, Weir MR, Fisher ML, Krichten. 1990. CM: Determinants of renal response to ACE inhibition in patients with congestive heart failure. *Circ* **82**(4) p III-386.
5. Gottlieb SS, **Robinson SW**, Krichten CM, and Fisher ML. 1991. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Circ* **84**(4) p II-470.
6. **Robinson SW**, Kaprielian Z, Kessler PD, and Fambrough DM. 1992. Rapid redistribution of the cardiac and fast-twitch isoforms of the calcium ATP-ase in sarcoplasmic reticulum membrane. *Circ* **86**(4): p I-350.
7. **Robinson SW**, Cho PW, Levitsky HI, Hruban RH, Acker MA, and Kessler PD. 1993. Vascular delivery of recombinant skeletal myoblasts to the myocardium. *Circ* **88**(4)pt2, p I-476.
8. **Robinson SW**, Cho PW, Acker MA, and Kessler PD. 1994. Arterial delivery of skeletal myoblasts to the heart. *J Cell Biochem* suppl 18D, p 531.
9. **Robinson SW**, Wilson PD, Fambrough DM. 1995. The Beta-2 subunit of the Na,K-ATPase is apically targeted in MDCK cells. *Mol. Bio. Cell*  **6**:402a.
10. **Robinson SW**, Zhou X, Huynh L, Fambrough DM. 1997. Development of an improved expression system for sodium pumps based upon simultaneous repression of endogenous pump expression and stimulation of exogenous pump expression in transfected MDCK cells. *Mol. Bio. Cell* **8:**83a.
11. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger RS, **Robinson SW**, Gotlieb SS. 1999 Long-term Efficacy of Coenzyme Q 10 Therapy for Congestive Heart Failure. *Circulation* **100**(18)Suppl, Nov. 2, I-674a.

Balke C. W., Goldman L., Sha Q. Chen-Izu Y., Shorofsky S. R., **Robinson S.W**., Wier W. G. Heterologously expressed H1 channels do not convert to ICa(TTX) channels. *Biophys. J***.** 82(1), part 2 of 2, 608a, 2002.

Chen-Izu Y, McCulle SL, Allen BM, Wehrens XH, **Robinson SW**, Soelller C, Cannell MB, Ward CW, Reiken SR, Marks AR, Balke CW, Izu LT. Geometry of Ryanodine Receptor Localization in Ventricular and Atrial Myocytes. *Biophysical Journal* (2004)

Jonathan Rogers, **Shawn Robinson**, Ashwani Khanna, Stacey McCulle, Sonia Blome, Anisha Bassi, Jianping Xu, Stephen Shorofsky, Mandeep Mehra Transforming Growth Factor-β Polymorphisms and Prediction of Clinical Outcome With Prophylactic Defibrillator Implantation in Chronic Heart Failure. *Circulation*, Oct 2007; **116**: II-635

1. Harris, K.M., Wawrzyniak, A.J., Marshall, J.M., Godoy, S.M., Marshall, J.P., **Robinson, S.R**., Krantz, D.S., & Gottlieb, S.S. (2011). The association of sodium intake and objective and subjective indicators of heart failure severity. *Journal of Cardiac Failure*, 17(8), S101.
2. Health-Related Quality of Life and Treatment Preferences in Ambulatory Heart Failure - Results from the REVIVAL Study; J. Stehlik1 , M. Mountis2 , D. Haas3 , M. Palardy4 , A. Ambardekar5 , J. Estep6 , G. Ewald7 , S. Russell8 , **S. Robinson9** , U. Jorde10, N. Jeffries11, C. Spino4 , J. T. Baldwin11, D. Mann7 , G. Stewart12, K. Aaronson4 , .. for the REVIVAL Investigators. The Journal of Heart and Lung Transplantation, Vol. 36, Issue 4, S211.
3. The REVIVAL Registry of Ambulatory Advanced Heart Failure: Baseline Characteristics; M. Palardy1 , R. McLean2 , S. Pamboukian3 , M. M. Kittleson4 , L. Warner Stevenson5 , P. Shah6 , G. Ewald7 , S. Russell8 , **S. Robinson9** , U. Jorde10, N. Jeffries11, C. Spino12, J. Baldwin13, D. L. Mann14, G. C. Stewart5 , K. Aaronson1 , F. REVIVAL Investigators1. The Journal of Heart and Lung Transplantation, Vol. 36, Issue 4, S196

### Major Invited Speeches

**Local**

1. Rehobeth Beach Sixth Annual Cardiovascular Symposium, Rehobeth Beach, DE.
2. “Gene Therapy for Cardiovascular Diseases” 1996
3. UMSOM Medical Grand Rounds: “Diastolic Dysfunction as a cause of CHF” 1999
4. 27th Annual Family Medicine Review Course, “Major Cardiovascular Trials: Implications for Clinical Practice”. 2001
5. UMSOM Medical Grand Rounds: “Hypertensive Cardiomyopathy: Myth or Reality” 2001
6. Mercy Medical Center, Medical Grand Rounds: “Diastolic Dysfunction and CHF” 2001
7. Harbor Hospital, Medical Grand Rounds: “Diastolic Dysfunction and CHF” 2001
8. UMSOM Family Medicine Grand Rounds “Lessons learned from major CHF trials; Current treatment strategies for Heart Failure” 2002
9. 29th Annual Family Medicine Review Course: Evaluating the Heart. 2003
10. 30th Annual Family Medicine Review Course: Update in Treating Hypertension 2004
11. Medical Grand Rounds: Re-evaluating Evidence-Based CHF Therapy, Potential

influence of Pharmacogenomics. 2007

1. Mercy Medical Grand Rounds: Re-evaluating Evidence-Based CHF Therapy, Potential

influence of pharmacogenomics 2007

1. Sixth Annual Scientific Forum On Cancer and Other Tobacco-Related Diseases, “Identifying Phosphodiesterase Type IV Genetic Associations with Cardiovascular Disease” 2008
2. Johns Hopkins Bayview Medical Center, Medical Grand Rounds, “Can genomics diminish the influence of Race in biomedical research?” 2010
3. National Medical Association, Update on Heart Failure Management, importance of distinction between HFrEF and HFpEF 2013
4. Maryland Learning Collaborative Workforce Training Million Hearts Healthcare Track, CHF and the use of ACE/ARBs, and other life-saving therapies 2013
5. Maryland Learning Collaborative Workforce Training Million Hearts Healthcare Track, Hypertension guidelines in 2014 – JNC 8 vs all the rest 2014
6. ACP Delaware Chapter, Lower Shores Annual Meeting, Heart Failure: Diagnosis and Treatment of patients with Reduced EF vs Preserved EF 2014
7. Maryland Learning Collaborative Workforce Training Million Hearts Healthcare Track Hypertension guidelines in 2015
8. ACP Maryland Chapter Annual Scientific Meeting, Use of Aspirin and NSAIDs in patients with Heart Disease 2016
9. Mercy Medical Grand Rounds, Use of Aspirin and NSAIDs in patients with Heart Disease 2016
10. Union Memorial Medical Grand Rounds, Use of Aspirin and NSAIDs in patients with Heart Disease 2016
11. National Medical Association, National Meeting, CHF Management in the first 30 days after hospital discharge 2017